MPH
Commercial- Indications
- Surgical bleeding, Hemorrhage
Company intelligence / Profile preview
Medafor
Minneapolis, Minnesota, United Statesmedafor.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Medafor developed plant-based microporous polysaccharide hemostatic agents shown to be safe and effective in controlling surgical and topical bleeding. Their flagship product, Arista MPH Hemostat, was indicated as an adjunctive agent when conventional means are ineffective or impractical. Clinical data demonstrated accelerated rate of bleeding control with a strong safety profile.
- Therapeutic areas
- OtherDermatologyHematology
- Modalities
- Device (Hemostatic agent)Biologic (Plant-based polysaccharide hemostat)
- Industry
- Consumable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Medafor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medafor.